University of California, Irvine

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of California, Irvine sits in the top decile of US sponsors by registered trial count (#96 of 15,742 sponsors by registered trial count).

368 total trials 74 currently recruiting 228 completed early-phase tilt top decile by trial count

University of California, Irvine: 368 sponsored US clinical trials, 74 recruiting.

University of California, Irvine sponsors 368 registered US clinical trials on ClinicalTrials.gov, 74 of them currently recruiting, and 228 completed. 27 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 6 trials.

Top-decile sponsor footprint

University of California, Irvine ranks in the top decile of sponsors by registered trial count (#96 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 61/100

228 of 258 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

368 total, page 5 of 8

TERMINATED Phase 3

Randomization of Botox for Stent Pain and Irritative Voiding Symptoms

NCT02078895

COMPLETED

A Pilot Study Non-Invasive Guidance for Therapeutic Ultrasound Treatment of Lower Back Muscle Injuries

NCT02169726

COMPLETED

Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol

NCT02057653

COMPLETED NA

FINGER Robot Therapy Study

NCT02048826

COMPLETED Phase 4

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

NCT02682498

COMPLETED

Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies

NCT01982357

COMPLETED

MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon

NCT01979848

COMPLETED Phase 1

Novel Treatment for Port Wine Stain Birthmarks

NCT01924273

TERMINATED NA

Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer

NCT02307552

COMPLETED NA

Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples

NCT02051101

COMPLETED NA

Office-based Percutaneous Ultrasound-guided Renal Biopsy

NCT02075684

COMPLETED Early Phase 1

IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

NCT01841619

COMPLETED

The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention

NCT02146885

COMPLETED

The Effect of Computerized Alcohol Screening and Brief Intervention (CASI) on Alcohol Consumption in Adolescent Patients in the Emergency Department

NCT01680627

COMPLETED

The Efficacy of Computerized Alcohol Screening and Intervention (CASI) in At-Risk Emergency Department and Trauma Patients

NCT01680614

COMPLETED

Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment

NCT01774552

COMPLETED NA

Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment

NCT01775722

COMPLETED NA

Closed-Loop Fluid Administration System Using Hemodynamic Monitors

NCT02020863

COMPLETED NA

Influence of Timing on Motor Learning

NCT01769326

COMPLETED

The Natural History of Human Stingray Injuries

NCT01685749

COMPLETED Phase 4

Retapamulin for Reducing MRSA Nasal Carriage

NCT01461668

COMPLETED NA

Randomized Study Comparing the Use of Epidural Analgesia to Intravenous Narcotics for Laparoscopic Colorectal Resection.

NCT02086123

COMPLETED NA

Twitter-enabled Mobile Messaging for Smoking Relapse Prevention

NCT01602536

COMPLETED Phase 1

1320 nm Nd:YAG Laser for Improving the Appearance of Onychomycosis

NCT01498393

COMPLETED NA

Radial Artery Access With Ultrasound Trial

NCT01605292

COMPLETED

Development of an Algorithm for Prediction of Onset of Hemodynamic Instability in Humans

NCT00581204

COMPLETED Phase 2

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

NCT01321437

COMPLETED

Assessing Cerebrovascular Reactivity Based on Cerebral Oximetry: a Pilot Study

NCT01483495

COMPLETED NA

RObotic Versus LAparoscopic Resection for Rectal Cancer

NCT01736072

COMPLETED

Development and Validation of a NIRS-based Sinusitis Screening

NCT01485484

COMPLETED NA

Goal Directed Fluid Management Based on Non-invasive Monitoring

NCT01883752

COMPLETED NA

Healthcare Provider Behavior and Children's Perioperative Distress

NCT01878747

COMPLETED NA

Test of an Intervention to Increase Physical Activity Among School Children

NCT01876602

COMPLETED

Accuracy of Dilution of EUS-FNA Pancreatic Cyst Fluid for Carcinoembryonic Antigen (CEA) Measurement

NCT01494077

COMPLETED

Role of Metabolic Enzymes in Non-Melanoma Skin Cancer

NCT02244749

TERMINATED Early Phase 1

Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus

NCT01313923

COMPLETED NA

Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance

NCT01209234

COMPLETED

Monitoring of Tissue Transfer Flaps by Modulated Imaging (MI) Spectroscopy

NCT00633503

COMPLETED

Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas Using Diffuse Optical Spectroscopic Imaging

NCT01263405

COMPLETED Phase 2

Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients

NCT01882985

COMPLETED NA

Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)

NCT01215721

COMPLETED

Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound With Fine Needle Aspiration (EUS/FNA), Direct Visualization, and Confocal Laser-induced Endomicroscopy-A Pilot Study

NCT01447238

COMPLETED Phase 3

Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction

NCT01212172

COMPLETED Phase 2

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

NCT01107665

COMPLETED

Noninvasive Optical Measurement of Critical Care Neonates

NCT01483703

COMPLETED

Monitoring the Response of Port Wine Stain Birthmarks to Laser Therapy With Wide-field Functional Imaging Technologies

NCT01333553

COMPLETED

Pain Blocking During Drug Administration or Blood Collection With Needles

NCT01166906

COMPLETED NA

Customized Acoustic Stimulation for the Treatment of Tinnitus

NCT01487447

COMPLETED NA

Effects of a High Protein Diet on Clinical Outcomes in Heart Failure

NCT01423266

COMPLETED

A Pilot Study Using Photo-plethysmographic (PPG) Camera

NCT01166867

← Previous Page 5 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 46
Phase 2 46
Phase 3 6
Phase 4 21

What is open in the University of California, Irvine pipeline

74 recruiting of 368 indexed (20% open); 228 completed (62%).

Phase mix: 27 late (III/IV) vs 92 early (I/II) (early-phase heavy).

Top condition: Cancer (6 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of California, Irvine: open-pipeline peers nationwide

Peers matched on 368 registered trials and 20% open enrollment, not the therapeutic-area sidebar.

University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 0%5%10%15%20%25% Total trials Recruiting share University of California, IrvineNorthwell HealthUNC Lineberger Comprehensive Cancer CenterRoswell Park Cancer InstituteNew York State Psychiatric InstituteUniversity of MiamiEndeavor HealthAcera SurgicalAlign Technology
University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of California, Irvine sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 368 trials (± recruiting share)

Sponsors near 20% open enrollment (± trial volume)

What to do with this University of California, Irvine page

368 registered trials is a research-attention snapshot, not an endorsement of University of California, Irvine or any single study.

  • 74 of University of California, Irvine's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cancer is the condition University of California, Irvine studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, Irvine pipeline card: 368 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.